Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOMENICA: Dostarlimab versus chemotherapy in first-line advanced/metastatic MMR-deficient endometrial cancer
KCT0009277Phase 3Not yet recruiting
- Sponsor
- Arcagy-Gineco
- Start
- May 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of dostarlimab in endometrial cancer (EC), sponsored by Arcagy-Gineco. Planned start May 2024; status: not yet recruiting.
02
Drugs
dostarlimab
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on KCT0009277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0009277.